Clinical trial
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in…
NCT00242736 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00242736 |
|---|---|
| Title | An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) |
| Official title | An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | GERD |
| Intervention type | Drug |
| Interventions | Esomeprazole |
| Enrollment | 350 |
| Start date | Oct 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Oct 21, 2005 |
| Last update posted | Mar 6, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: